Keyword: Xtandi

Astellas will invest $255 million in production and R&D as it pushes into gene and cell therapies for cancer and other diseases.

Astellas narrowed the field of creative cancer care ideas in its annual C3 contest to three finalists who will pitch to an expert panel of judges.

Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.

Opdivo is priced in China at half its U.S. cost; Novartis names new chief for scandal-hit Korea unit; GSK's Indian consumer unit attracts new buyers.

Pfizer and Astellas are picking up the pace on Xtandi's bid for approval in hormone-sensitive prostate cancer as its new J&J rival Erleada revs up.

Pfizer halts production at a legacy Hospira plant; China works to offer Indian drugmakers streamlined access; Roivant's Sinovant debuts with 11 assets.

Pfizer and Astellas’ prostate cancer med Xtandi nabbed broader FDA approval, setting it up for a head-to-head fight with J&J’s Erleada.

Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.